Laboratory of ImmunoViroTherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
Cancer Res. 2021 Jun 15;81(12):3149-3155. doi: 10.1158/0008-5472.CAN-20-4026. Epub 2021 Mar 9.
Cancer immunotherapy has revolutionized the way tumors are treated. Nevertheless, efficient and robust testing platforms are still missing, including clinically relevant human tumor assays that allow pretreatment testing of cancer therapies and selection of the most efficient and safe therapy for a specific patient. In the case of immunotherapy, this testing platform would require not only cancer cells, but also the tumor microenvironment, including immune cells. Here, we discuss the applications of patient-derived tumor organoid cultures and the possibilities in using complex immune-organoid cultures to provide preclinical testing platforms for precision cancer immunotherapy.
癌症免疫疗法彻底改变了肿瘤的治疗方式。然而，目前仍然缺乏高效、强大的检测平台，包括具有临床相关性的人类肿瘤检测，这种检测可以在治疗前对癌症疗法进行测试，并为特定患者选择最有效和最安全的疗法。在免疫疗法的情况下，这种检测平台不仅需要癌细胞，还需要肿瘤微环境，包括免疫细胞。在这里，我们讨论了患者来源的肿瘤类器官培养物的应用，以及使用复杂的免疫类器官培养物为精准癌症免疫疗法提供临床前检测平台的可能性。
